Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir-Reference-Cited by-同舟云学术

Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

Published:2015-07-03 Issue:11 Volume:60 Page:3465-3472
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Fong Tse-Ling,Tien Andy,Jo Kahee J.,Chu Danny,Cheung Eddie,Mena Edward A.,Phan Quang-Quoc,Yu Andy S.,Mohammed Wafa,Velasco Andrew,LeDuc Vinh-Huy,Nguyen Nickolas,Han Steven-Bui,Chang Mimi,Bae Ho S.,Cho Yong-Won,Tong Myron J.,Cooper Stewart L.

Funder

Gilead Sciences

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-015-3775-9.pdf

Reference39 articles.

1. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986;6:167–172.

2. Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690–698.

3. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727–2734. doi: 10.1007/s10620-010-1179-4 .

4. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527.

5. Kuo L-F, Lee C-M, Hung C-H, et al. High risk of hepatitis B virus reactivation in nucleos(t)e analogue-induced hepatitis B e antigen seroconverters older than 40 years. Dig Dis Sci. 2014;59:2580–2587.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Management of Patients with HBV Infection;Current Hepatology Reports;2024-01-23

2. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis;JHEP Reports;2023-01

3. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients;Hepatology Research;2022-02-21

4. No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B;Journal of Viral Hepatitis;2021-08-16

5. Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study;Antiviral Therapy;2020